



## Wednesday, February 22, 2023

13:00-14:30	<b>PLENARY INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)			
14:30-16:00		<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)
16:15-17:45	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)
18:00-19:00	<b>OPENING CEREMONY</b> <u>Tadej Battelino</u> - Opening remarks  <b>OPENING LECTURE</b> <u>Chantal Mathieu</u> – The new face of diabetes			
19:00-20:00	<b>NETWORKING RECEPTION (in the Exhibition Area)</b>			

## Thursday, February 23, 2023

08:30-10:00	<b>PLENARY SESSION – CGM USE IN TYPE 2 DIABETES AND BEYOND</b>  <b><u>Rich Bergenstal</u></b> - Use of CGM with people with diabetes type 2 not treated with insulin <b><u>Lalanth Leelarathna</u></b> - Use of CGM with people with diabetes type 2 treated with basal insulin only <b><u>Melissa Putman</u></b> - Use of CGM in the cystic fibrosis population <b><u>Satish Garg</u></b> – The vision of the future of CGM in type 2 diabetes
10:00-10:30	<b>COFFEE BREAK, EXHIBITION &amp; E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>
10:30-12:00	<b>INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)
12:00-13:00	<b>LUNCH BREAK, EXHIBITION &amp; E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>

13:00-14:30	<b>PARALLEL SESSION RESOLVING HYPOGLYCEMIA</b>	<b>PARALLEL SESSION DECISION SUPPORT SYSTEMS</b>	<b>PARALLEL SESSION TECHNOLOGY USE IN PREGNANCY</b>	<b>PARALLEL SESSION EXERCISE IN DIABETES</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>Oral (1)</b>
	<p><b>Simon Heller</b> - What reduction in hypoglycemia from interventions should be considered clinically meaningful</p> <p><b>Pratik Choudhary</b> - Difference between CGM detected and patient reported hypoglycemia</p> <p><b>Frans Pouwer</b> - The impact of hypoglycemia: What do studies using patient reported outcomes tell us</p> <p><b>Bastiaan de Galan</b> - Learnings from the Hypo-RESOLVE project</p>	<p><b>Revital Nimri</b> - Real-world data on the use of decision support systems</p> <p><b>Peter Jacobs</b> - Incorporating explainability and interpretability into AI-enabled decision support systems?</p> <p><b>Leah Wilson</b> - Artificial intelligence and decision support systems</p> <p><b>Korey Hood</b> - Patient reported outcomes in closed loop studies</p>	<p><b>Sarit Polsky</b> - Do we need pregnancy specific closed-loop algorithms?</p> <p><b>Lois Donovan</b> - Psychosocial impact of using closed-loop systems during pregnancy</p> <p><b>Helen Murphy</b> - Automated insulin delivery in type 1 diabetes pregnancy - are we nearly there yet?</p> <p><b>Yariv Yogev</b> - Should we suggest weight loss during pregnancy for obese women with diabetes?</p>	<p><b>Kirsten Nørgaard</b> - Exercise with AID</p> <p><b>Dessi Zaharieva</b> - Is technology useful for breaking down barriers to exercise in diabetes?</p> <p><b>Lia Bally</b> - Physical activity with long and ultra-long-acting basal insulins</p> <p><b>Ali Cinar</b> - Automated detection of meals and exercise events in people with diabetes</p>			
14:30-15:00	<b>COFFEE BREAK, EXHIBITION &amp; E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>						
15:00-16:30	<b>INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)						

16:40-18:10	<b>PARALLEL SESSION EMERGING TREATMENT OPTIONS FOR OBESITY AND TYPE 2 DIABETES</b>	<b>PARALLEL SESSION JDRF SESSION - CONTINUOUS KETONE MONITORING FOR TYPE 1 DIABETES</b>	<b>PARALLEL SESSION AID EXPERIENCE IN THE REAL- WORLD</b>	<b>PARALLEL SESSION CLOSED-LOOP IN ACTION</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>Oral (2)</b>
	<p><b><u>Mojca Jensterle Sever</u></b> - GLP-1 Analogs for the treatment of Obesity</p> <p><b><u>Juan Frias</u></b> - Unimolecular multiagonists (dual and triple) for the management of obesity and cardiorenal risk – An update</p> <p><b><u>Julio Rosenstock</u></b> - Challenging treatment guidelines: Reversing type 2 DM from Day One</p> <p><b><u>Walter Pories</u></b> - Bariatric surgery: An update</p>	<p><b><u>David O’Neal</u></b> - Clinical need for continuous ketone monitoring integrated into CGM devices (i.e. CGM-CKM)</p> <p><b><u>Rodica Busui</u></b>: SGLT inhibitors in T1D: DKA risk and DKA risk mitigation strategies, especially CGM-CKM, to enable therapy use for heart and kidney health</p> <p><b><u>Idan Tamir</u></b>: Pre-clinical development of CGM-CKM</p> <p><b><u>Shridhara Alva</u></b>: Feasibility and performance of a continuous ketone monitoring sensor</p>	<p><b><u>Eric Renard</u></b> – French Children</p> <p><b><u>Regis Radermecker</u></b> – In Belgium</p> <p><b><u>Emma Wilmot</u></b> – In the United Kingdom</p> <p><b><u>Helen Murphy</u></b> – In pregnancy</p>	<p><b><u>Roman Hovorka</u></b> - Closing the loop – from cradle to mature age</p> <p><b><u>Ahmad Haidar</u></b> - Closed-loop with adjunct therapies</p> <p><b><u>Stuart Weinzimer</u></b> - Postprandial glucose control in advanced hybrid closed-loop systems</p> <p><b><u>Peter Jacobs</u></b> - Leveraging behavioral and physiologic patterns collected from wearable sensors and a smart-home to augment next-generation closed-loop algorithms</p>			

Friday, February 24, 2023

08:00-08:50	<b>INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)						
09:00-10:00	<b>PARALLEL SESSION CARDIOVASCULAR DIABETES</b>	<b>PARALLEL SESSION DERMATOLOGY IN DIABETES</b>	<b>PARALLEL SESSION WEEKLY INSULINS</b>	<b>PARALLEL SESSION NON-INVASIVE GLUCOSE MONITORING: REALITY VS. HYPE</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>Oral (3)</b>
	<p><b>Antonio Ceriello</b> - Cardiovascular outcome trials (CVOT): Which role for risk factors control?</p> <p><b>Oliver Schnell</b> - Cardiovascular outcome trials (CVOTs) in diabetes - A success story that has changed the landscape of diabetes therapy</p> <p><b>Viral Shah</b> - Causes of cardiovascular disease and insulin resistance in type 1 diabetes</p>	<p><b>Irl Hirsch</b> - Skin and the insulin pump: New findings</p> <p><b>Laurel Messer</b> - Skin integrity, tips, tricks, and hacks for sustained device use</p> <p><b>Sumita Pennathur</b> - Long term solutions for improving infusion site challenges for insulin pumps</p>	<p><b>Julio Rosentock</b> - Update on weekly Icodec Insulin: Lessons from the ONWARD Clinical Development Program</p> <p><b>Steven Edelman</b> - Once weekly insulins in Type 1 diabetes: Safety, efficacy and does it address an unmet need?</p> <p><b>Juan Frias</b> - Once Weekly Basal Insulin Fc (BIF): An update on the type 2 diabetes clinical development program</p>	<p><b>Bruno Thuillier</b> - Non-invasive glucose monitoring: Breath, a realistic option?</p> <p><b>Christophe de Block</b> - Continuous ketone monitoring</p> <p><b>Anders Weber</b> - Raman Ni-BGM from conception to real world clinical device; are we there yet?</p>			
10:00-10:30	<b>COFFEE BREAK, EXHIBITION &amp; E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>						
10:30-12:00	<b>INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)						
12:00-13:00	<b>LUNCH BREAK, EXHIBITION &amp; E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>						

13:00-14:30

**ATTD YEARBOOK SESSION**

**Satish K. Garg** - Virtual clinics for diabetes care

**Klemen Dovc** - Continuous and intermittent glucose monitoring

**Rayhan Lal** - Insulin delivery hardware: Pumps and pen

**Thomas Pieber** - New insulins, biosimilars and insulin therapy

**Revital Nimri** - Closed-loop and artificial intelligence-based decision support systems

**Marc Clements** - Using digital health technology to prevent and treat diabetes

**Jennifer Yamamoto** - Technology and pregnancy

**David Maahs** - Diabetes technology and therapy in the pediatric age group

**Dessi Zaharieva** - Advances in exercise and nutrition as therapy in diabetes

**Gregg Simonson / Thomas Martens** - Primary care and diabetes technologies and treatments

**Stuart Weinzimer** - Real-world diabetes technology: Overcoming barriers & disparities

**Alon Liberman** - Diabetes technology and the human factor

**Desmond Schatz** - Immune interventions and restorative therapies in type 1 diabetes

**Irl Hirsch** - New medications for the treatment of diabetes

**Viral Shah** - Obesity and diabetes

14:30-15:00

**COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES**

15:00-16:30

**INDUSTRY SYMPOSIUM** (not included in the main event CME/CPD credit)

16:40-18:10	<b>PARALLEL SESSION SOME MORE HIGHLIGHTS IN DIABETES</b>	<b>PARALLEL SESSION TIMES IN RANGES</b>	<b>PARALLEL SESSION ADVANCES IN FULLY AUTOMATED CLOSED-LOOP</b>	<b>PARALLEL SESSION FEAR OF HYPERGLYCEMIA</b>	<b>PARALLEL SESSION TECHNOLOGY FOR THE HEALTHY AGING OF OLDER PEOPLE WITH DIABETES</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> <small>(not included in the main event CME/CPD credit)</small>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> <small>(not included in the main event CME/CPD credit)</small>	<b>Oral (4)</b>
	<p><b><u>Guido Freckmann</u></b> - Why do CGM performance assessments need more standardization?</p> <p><b><u>Gregory Forlenza</u></b> - Can Hybrid Closed Loop and/or Verapamil Prolong Islet Survival in new onset type 1 diabetes? Results from the JDRF CLVer Trial</p> <p><b><u>Francesco Rubino</u></b> - Surgical treatment of obesity and type 2 diabetes: Outcomes, mechanisms and future perspectives</p> <p><b><u>Nebojsa Lalic</u></b> - The use of SAP In pregnancy: Comparison of the initiation of the treatment before and after conception</p>	<p><b><u>Thomas Danne</u></b> - What is the clinical relevance of TIR/TAR 70-140 mg/dl for T1D and T2D?</p> <p><b><u>Peter Adolfsson</u></b> - Time in tight range in type 1 diabetes</p> <p><b><u>Tadej Battelino</u></b> - Time in tight range in type 2 diabetes</p> <p><b><u>David Rodbard</u></b> - TIR and other Times in Ranges are better than HbA1c as metrics for quality of glycemc control</p>	<p><b><u>Patricio Colmegna</u></b> - Automated control meets behavior: Human-machine co-adaptation of the artificial pancreas</p> <p><b><u>Michael Riddell</u></b> - Closing the loop on exercise</p> <p><b><u>Klemen Dovc</u></b> - Ultra-rapid insulin and anticipatory algorithms</p> <p><b><u>Boris Kovatchev</u></b> - Fully-automated closed-loop control: Challenges and potential solutions</p>	<p><b><u>Bruce Bode</u></b> - Management of hyperglycemia in the hospital using closed-loop systems</p> <p><b><u>Irl Hirsch</u></b> - Update on glycemc targets in the ICU</p> <p><b><u>Nataša Bratina</u></b> - Avoiding hyperglycemia from diabetes onset</p> <p><b><u>Alon Liberman</u></b> - Fear of hyperglycemia in parents of children with type 1 diabetes</p>	<p><b><u>Medha Munshi</u></b> - Why healthy aging with diabetes is a challenge?</p> <p><b><u>Tali Cukierman-Yaffe</u></b> - Adverse outcomes of hyperglycemia &amp; hypoglycemia in older people with diabetes- how should the recommended target % TIR be determined?</p> <p><b><u>Richard Pratley</u></b> - The use of CGM in older people with diabetes</p> <p><b><u>David O'Neal</u></b> - The use of hybrid closed systems in older people with diabetes</p>			
19:00-21:30	<b>OFF-SITE ATTD PARTNER EVENT</b> (not included in the main event CME/CPD credit)							

## Saturday, February 25, 2023

08:00-09:10	<b>INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)						
09:30-11:00	<b>PARALLEL SESSION REMOTE TREATMENT OF DIABETES</b>	<b>PARALLEL SESSION NUTRITION AND FOOD TECHNOLOGIES</b>	<b>PARALLEL SESSION DESPAIR AND SELF- HARM &amp; DIABETES TECHNOLOGY</b>	<b>PARALLEL SESSION PRACTICAL ISSUES IN DAILY LIFE OF PEOPLE WITH DIABETES</b>	<b>Oral (5)</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> <small>(not included in the main event CME/CPD credit)</small>	<b>Oral (6)</b>
	<p><b><u>Mark Clements</u></b> – Population health management in the digital diabetes era</p> <p><b><u>Paul Wadwa</u></b> - Challenges in implementing telehealth for diabetes care</p> <p><b><u>David Maahs</u></b> - ECHO study - Delivering tele-education on diabetes to primary care physicians in underserved areas</p> <p><b><u>Robert Ratner</u></b> - Outcomes of continuous remote care in pre-diabetes and type 2 diabetes</p>	<p><b><u>Andrea Scaramuzza</u></b> – Strategies for mitigating glycemic excursions following unannounced meals with existing technologies</p> <p><b><u>Maya Laron-Hirsh</u></b> - Complex meal handling with advanced hybrid closed-Loop system</p> <p><b><u>Maria Vasiloglou</u></b> - What healthcare professionals and end-users need in image-based nutrition apps</p> <p><b><u>Michal Gillon-Keren</u></b> Mobile application for carbohydrate counting - personalized nutrition</p>	<p><b><u>Lori Laffel</u></b> - Addressing opportunities to Improve glycemic control and limit diabetes distress</p> <p><b><u>Katharine Barnard-Kelly</u></b> - Understanding clinical relevance on a PRO</p> <p><b><u>Marc Breton</u></b> - Machine learning and big data to identify individuals at risk</p> <p><b><u>Marissa Town</u></b> - What matters to the person with diabetes when choosing diabetes technologies</p>	<p><b><u>John Pemberton</u></b> - The issues with using CE Mark as a valid proxy for continuous glucose monitoring systems accuracy for people with type 1 diabetes</p> <p><b><u>Emma Wilmot</u></b> - Helping adults choose a safe and effective CGM in light of new national guidance</p> <p><b><u>Ramzi Ajjan</u></b> - Is it easy to use time in range (TIR) for daily management of diabetes?</p> <p><b><u>Mark Evans</u></b> - The regulations around driving and diabetes</p>			



11:00-11:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
11:30-13:00	<b>PARALLEL SESSION DIABETES INDIA</b>	<b>PARALLEL SESSION JDRF SESSION - MONITORING PRE- SYMPTOMATIC TYPE 1 DIABETES: WHICH TECHNOLOGY FOLLOWS AUTOANTIBODY DETECTION?</b>	<b>PARALLEL SESSION DATA SCIENCE IN DIABETES</b>	<b>PARALLEL SESSION GLUCOSE MANAGEMENT IN THE PEDIATRIC AND ADULT FEMALE POPULATION</b>	<b>Oral (7)</b>	<b>PARALLEL SESSION FIGHTING DISPARITIES</b>	<b>Oral (8)</b>
	<p><b><u>Banshi Saboo</u></b> - Introduction</p> <p><b><u>Amit Gupta</u></b> - Personalized medicine to precision medicine: India is changing</p> <p><b><u>Rakesh Parikh</u></b> - Diabetes technology - the make in India story</p> <p><b><u>Manoj Chawla</u></b> - Diabetes management in India - challenges &amp; tech solutions</p> <p><b><u>Mithun Bhartia</u></b> - Opportunities and Threats analysis (SWOT) of blood sugar monitoring in India</p> <p><b><u>Jothydev Kesavadev</u></b> - Do it yourself artificial pancreas: The affordable Indian experiences</p>	<p><b><u>Sanjoy Dutta</u></b> - Introduction</p> <p><b><u>Michael Haller</u></b> - The strengths and limitations of monitoring via OGTT</p> <p><b><u>Chantal Mathieu</u></b> - The evidence for alternative monitoring technologies</p> <p><b><u>Kimber Simmons</u></b> - What's feasible in the clinical care setting?</p>	<p><b><u>Amy Criego</u></b> - Improved data collection: Moving CGM reports from the patient directly to the EMR</p> <p><b><u>David Scheinker</u></b> - Algorithm-enabled RPM for T1D; lessons from the 4T study for a continuously learning health system</p> <p><b><u>Gregory Forlenza</u></b> - Data ownership and use of data aggregators in clinical care</p> <p><b><u>Mark Clements</u></b> - Deep learning to predict diabetes outcome</p>	<p><b><u>Eda Cengiz</u></b> - Technological gadgets: What is available to girls and women with diabetes</p> <p><b><u>Darja Šmigoc Schweiger</u></b> - Gender differences in cardiovascular risk markers in young population with type 1 diabetes</p> <p><b><u>Dessi Zaharieva</u></b> - Sex differences in the management of exercise in the pediatric and adult population</p> <p><b><u>Chiara Fabris</u></b> - Insulin dosing in women with T1D: Is there a need for tailored solutions?</p> <p><b><u>Katharine Barnard – Kelly</u></b> - Psycho-behavioral barriers to optimal glucose management in women with T1D across the ages</p>		<p><b><u>Lori Laffel</u></b> - Understanding and overcoming health disparities in use of diabetes technologies</p> <p><b><u>Partha Kar &amp; Jazz Sethi</u></b> - Fighting disparities: Different worlds</p> <p><b><u>David Maahs</u></b> - Bridging Disparities in Type 1 Care in the US</p> <p><b><u>Viswanathan Mohan</u></b> - Advocacy and adoption of technology and disparities in India</p>	

13:00-13:45	LUNCH, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
13:45-14:45	<b>PARALLEL SESSION DIABETES TECHNOLOGY AND WASTE: HOW TO TURN GREENER?</b>	<b>PARALLEL SESSION EMERGING TECHNOLOGIES FOR DIABETES</b>	<b>PARALLEL SESSION ISPAD SESSION</b>	<b>PARALLEL SESSION MIND THE FOOT!</b>	<b>Oral (9)</b>	<b>EUDF/ATTD SESSION: HOW TO UNLOCK THE FULL POTENTIAL OFFERED BY DATA AND DIGITAL HEALTH?</b>	<b>Oral (10)</b>
	<p><b>David Kerr</b> - The greening of diabetes care in America</p> <p><b>Lutz Heinemann</b> - Diabetes technology and waste: How to turn greener? - The EU point of view</p> <p><b>Matthias Axel Schweitzer</b> - Diabetes technology and waste: How to turn greener? - The manufacturers' point of view</p>	<p><b>Simon Friedman</b> – Replacing pumps with light controlled insulin delivery</p> <p><b>Idan Tamir</b> - Continuous Lactate Monitoring (CLM) – A new paradigm for monitoring high-risk diabetic patients</p> <p><b>Claudio Cobelli &amp; Alfonso Galderisi</b> - Beyond the glucose-centric diabetes management: The path to multiple sensing</p>	<p><b>Roque Cardona-Hernandez</b> - Global Registry data: Diabetes Technology impact</p> <p><b>Julia Lawton</b> - Psychological impact of technology: What is most relevant?</p> <p><b>Jamie Wood</b> - Diabetes technology access in low and middle low-income countries: Now or later</p>	<p><b>Andrew Boulton</b> - New evidence-base therapies for complex diabetic foot wounds</p> <p><b>Julia Mader</b> - Monitoring of diabetic foot disease</p> <p><b>Prash Vas</b> - Developing a functional multidisciplinary foot service of the future: Integrating team working and technology</p>		<p>TBD</p>	

14:55–15:55	<b>PLENARY SESSION SCREENING AND PREVENTION OF TYPE 1 DIABETES</b>  <b><u>Rachel Besser</u></b> – Screening of general population – Current status around the world <b><u>Laura Jacobsen</u></b> – Emerging biomarkers of responses to immunotherapies <b><u>Jay Skyler</u></b> – Stem cell approaches to type 1 diabetes
15:55-16:25	<b>CLOSING REMARKS</b>  <b>100 YRS INSULIN PRIZE</b>
16:25	<b>FAREWELL REFRESHMENTS</b>